- Home
- GENC vs ZNTL Comparison
GENC vs ZNTL Comparison
Compare GENC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- ZNTL
- Stock Information
- Founded
- GENC 1894
- ZNTL 2014
- Country
- GENC United States
- ZNTL United States
- Employees
- GENC N/A
- ZNTL N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- ZNTL Health Care
- Exchange
- GENC Nasdaq
- ZNTL Nasdaq
- Market Cap
- GENC 210.9M
- ZNTL 105.8M
- IPO Year
- GENC N/A
- ZNTL 2020
- Fundamental
- Price
- GENC $13.86
- ZNTL $1.20
- Analyst Decision
- GENC
- ZNTL Buy
- Analyst Count
- GENC 0
- ZNTL 7
- Target Price
- GENC N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- GENC 24.0K
- ZNTL 1.4M
- Earning Date
- GENC 06-27-2025
- ZNTL 08-08-2025
- Dividend Yield
- GENC N/A
- ZNTL N/A
- EPS Growth
- GENC N/A
- ZNTL N/A
- EPS
- GENC 0.99
- ZNTL N/A
- Revenue
- GENC $113,166,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- GENC N/A
- ZNTL N/A
- Revenue Next Year
- GENC N/A
- ZNTL N/A
- P/E Ratio
- GENC $13.89
- ZNTL N/A
- Revenue Growth
- GENC 7.70
- ZNTL N/A
- 52 Week Low
- GENC $10.80
- ZNTL $1.01
- 52 Week High
- GENC $24.88
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- GENC 47.63
- ZNTL 43.44
- Support Level
- GENC $13.99
- ZNTL $1.31
- Resistance Level
- GENC $15.45
- ZNTL $1.39
- Average True Range (ATR)
- GENC 0.73
- ZNTL 0.13
- MACD
- GENC -0.04
- ZNTL -0.02
- Stochastic Oscillator
- GENC 13.78
- ZNTL 6.83
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.